Topo Ⅱ在大肠癌中的表达及意义  

EXPRESSION AND CLINICAL SIGNIFICANCE OF TOPO Ⅱ IN COLORECTAL CARCINOMA

作　　者：刘荣霞[1] 白江涛[1] 孙全昌[1] 郑纪宁[1] 

机构地区：[1]承德医学院,河北承德067000

出　　处：《承德医学院学报》2012年第3期237-239,共3页Journal of Chengde Medical University

摘　　要：目的:探讨大肠癌组织多药耐药基因(MDR-1)产物DNA拓扑异构酶Ⅱ(Topo Ⅱ)的表达及与大肠癌临床病理特征的关系。方法:采用免疫组织化学法检测95例大肠癌组织Topo Ⅱ的表达。结果:95例大肠癌患者中,Topo Ⅱ阳性表达率为57.9%(55/95)。大肠癌Topo Ⅱ的表达与性别、肿瘤大小、发病部位、分化程度、临床分期及有无淋巴结转移无关(P>0.05);与年龄有关,≥60岁者Topo Ⅱ的阳性表达率明显高于<60岁者(P<0.01)。结论:大肠癌中Topo Ⅱ的表达与年龄有关,检测大肠癌Topo Ⅱ的表达对选择化疗药物具有指导意义。Objective：To investigate the relationships between multidrug resistance gene product Topo Ⅱ expression and pathological features of eolorectal carcinoma.Methods：The Topo Ⅱ expression of 95 eases colorectal carcinoma patients was detected by SP immunohistochemical methods.Results：In 95 cases eolorectal carcinoma patients, the positive rate of Topo Ⅱ was 57.9% （55/95）. The Topo Ⅱ expression of colorectal carcinoma had no relations with sex, tumor size, location of tumor, differentiation degree, Duke＇s stage and lymph node metastasis （P〉 0.05）. The Topo Ⅱ expression of eolorectal carcinoma related to age： the positive rate of Topo Ⅱ expression of patients ≥ 60 years old was obviously higher than that of patients 〈 60 （P〈 0.01 ）.Condusions：Topo Ⅱ expression in eolorectal carcinoma has relations with age, and detection of Topo Ⅱ expression in eolorectal carcinoma has guiding significance for choosing ehemotherapeuties.

关 键 词：TOPO Ⅱ 多药耐药基因 大肠癌 免疫组织化学 

分 类 号：R735.3[医药卫生—肿瘤]